Asset / Drug

Foundayo

Drug and asset intelligence for Foundayo with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

Pharmacotherapy

StrategyJune 16, 2026

CVS Caremark will cover Foundayo starting June 1 and Zepbound from October 1, allowing eligible patients to pay as low as $25 monthly.

StrategyJune 16, 2026

In clinical trials, Foundayo demonstrated significant weight loss in women across all stages of menopause, with losses up to 30.4 lbs.

CompetitiveJune 16, 2026

Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.

No catalysts indexed for this entity yet.

Topline Data

Monitor patient uptake and any changes in competitor coverage policies following this announcement.

June 16, 2026 · N/A

Topline Data

Monitor further trial results and potential regulatory submissions for Foundayo, as well as competitor responses in the GLP-1 market.

June 16, 2026 · N/A

Topline Data

Monitor further data releases and regulatory submissions for Foundayo, as well as competitor responses.

June 16, 2026 · N/A

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.